Paper
Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series
Published Apr 1, 2012 · Dharmesh Shah, J. Sinn
Acta Paediatrica
Q1 SJR score
50
Citations
4
Influential Citations
Abstract
Background: Octreotide, a somatostatin analogue, is used for the management of patients with refractory chylothorax although its safety and efficacy in neonates have not been evaluated in controlled clinical trials. We present one of the largest case series about the use of octreotide in congenital idiopathic chylothorax.
Case ReportStudy Snapshot
Octreotide is a safe and effective treatment for congenital idiopathic chylothorax in neonates, with potential for future controlled clinical trials.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
CONGENITAL CHYLOTHORAX TREATED WITH OCTREOTIDE
Octreotide infusion shows promise as a promising alternative to surgery for recalcitrant cases of congenital chylothorax in newborns, with respiratory improvement and clinical symptoms resolved in 12 and 10 days.
2014·12citations·A. Safari et al.·KAUMS Journal
KAUMS Journal
Octreotide for the treatment of chylothorax in neonates.
Octreotide's effectiveness in treating chylothorax in neonates is unclear, and a prospective registry and randomized controlled trial are needed to confirm its safety and efficacy.
2010·111citations·Animitra Das et al.·The Cochrane database of systematic reviews
The Cochrane database of systematic reviews
Idiopathic congenital chylothorax presented with severe hydrops and treated with octreotide in term newborn
Octreotide therapy rapidly improved and the chylothorax disappeared in a newborn with congenital chylothorax and severe hydrops, demonstrating its potential as an effective treatment for this condition.
2009·31citations·A. Bulbul et al.·The Journal of Maternal-Fetal & Neonatal Medicine
The Journal of Maternal-Fetal & Neonatal Medicine
Is octreotide a risk factor in necrotizing enterocolitis?
Octreotide use in neonates may increase the risk of necrotizing enterocolitis, requiring multiple intestinal resections.
2008·32citations·C. Reck-Burneo et al.·Journal of pediatric surgery
Journal of pediatric surgery
[Octreotide for conservative management of postoperative chylothorax in the neonate].
Octreotide effectively resolved postoperative chylothorax in a premature neonate, avoiding surgical treatment and reducing adverse effects without adverse effects.
2007·5citations·G. Rocha et al.·Acta medica portuguesa
Acta medica portuguesa
Octreotide therapy for chylothorax in infants and children: A brief review
Octreotide therapy has shown success in treating chylothorax in infants and children, but optimal dosing, duration, and discontinuation strategies remain unclear.
2006·75citations·Radley Helin et al.·Pediatric Critical Care Medicine
Pediatric Critical Care Medicine
The use of octreotide to treat congenital chylothorax.
Octreotide effectively treats congenital chylothorax in patients with Turner's syndrome, achieving complete resolution after 5 days of continuous therapy.
2006·39citations·A. Paget-Brown et al.·Journal of pediatric surgery
Journal of pediatric surgery
Citations
Persistent Postoperative Chylothorax in a Neonate Undergoing Primary Esophageal Atresia Repair Successfully Treated by Open Thoracic Duct Ligation: A Case Report
Open thoracic duct ligation is an effective treatment for persistent postoperative chylothorax in neonates, particularly in countries with limited resources.
2024·0citations·Z. Zvizdic et al.·Cureus
Cureus
Congenital Chylothorax of the Newborn: A Systematic Analysis of Published Cases between 1990 and 2018
Respiratory support, pleural drainages, TPN, and MCT diet as octreotide remain the cornerstones of CCT management in newborns, with potential for life-threatening cases.
2021·34citations·B. Resch et al.·Respiration
Respiration
The use of high dose octreotide in management of neonatal chylothorax: Review.
High doses of octreotide can safely be titrated in neonatal chylothorax treatment without significant side effects.
2021·5citations·M. Alhasoon·Journal of neonatal-perinatal medicine
Journal of neonatal-perinatal medicine
Non-immune hydrops fetalis secondary to congenital chylothorax with diffuse interstitial lung disease: a diagnostic conundrum
Congenital pulmonary lymphangiectasia is the most likely diagnosis for a Chinese infant with hydrops fetalis due to bilateral congenital chylothorax and diffuse interstitial lung disease.
2021·0citations·A. Ngeow et al.·BMJ Case Reports
BMJ Case Reports
Conservative management of chylothorax in infants using octreotide
Chylothorax in infants can be managed conservatively using octreotide, which can effectively reduce the accumulation of lymphatic fluid in the pleural space.
2020·0citations·Anusiri Inugala·International Surgery Journal
International Surgery Journal
Propranolol for the Treatment of Lymphatic Malformations in a Neonate - A Case Report and Review of Literature.
Propranolol at a lower dose of 0.5 mg/kg/day effectively improved clinical symptoms in a premature neonate with trisomy 21, highlighting the need for individual patient and disease state characteristics to guide treatment decisions.
2020·13citations·Caren J. Liviskie et al.·The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
Combined Chylothorax and Chylous Ascites Complicating Liver Transplantation: A Report of a Case and Review of the Literature
Chyle leaks after liver transplantation can be successfully managed conservatively with dietary modifications, nil per os, and somatostatin analogues.
2019·1citation·T. Ivanics et al.·Case Reports in Transplantation
Case Reports in Transplantation
Analysis of the etiology and treatment of chylothorax in 119 pediatric patients in a single clinical center.
In our center, idiopathic factors are the main cause of chylothorax in neonates, with iatrogenic factors being more significant in infant and older-than-1-year groups.
2019·14citations·Chun Wu et al.·Journal of pediatric surgery
Journal of pediatric surgery
Neonatal Chylothoraces: A 10-Year Experience in a Tertiary Neonatal Referral Centre
Neonatal chylothorax is uncommon but high-risk, and affected neonates require high healthcare utilisation, with MCT feeds stabilizing pleural fluid output and no consensus on surgical intervention indications.
2019·18citations·Marie K White et al.·Case Reports in Pediatrics
Case Reports in Pediatrics